Halozyme Therapeutics, Inc. (NASDAQ:HALO) Holdings Lowered by Park Place Capital Corp

Park Place Capital Corp lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 33.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 904 shares of the biopharmaceutical company’s stock after selling 451 shares during the quarter. Park Place Capital Corp’s holdings in Halozyme Therapeutics were worth $43,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares during the period. Toth Financial Advisory Corp purchased a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $57,000. FSC Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics during the third quarter valued at $65,000. CWM LLC lifted its holdings in shares of Halozyme Therapeutics by 77.5% during the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 668 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Halozyme Therapeutics by 173.6% in the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,028 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Performance

HALO stock opened at $55.63 on Friday. The stock has a market capitalization of $7.08 billion, a PE ratio of 18.42, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The company has a 50 day moving average price of $49.36 and a 200 day moving average price of $54.18.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HALO. HC Wainwright boosted their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. JMP Securities upped their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.